Cancer Research and Treatment

Original Articles

Immunosuppressive Tumor Microenvironment in Colorectal Cancer Lung Metastases: Implications for Recurrence After Metastasectomy: Minsuk Kwon, Min-Kyue Shin, Minae An, Yeong Jeong Jeon, Tae Hee Hong, Jung Kyong Shin, Sung Hee Lim, Yoonah Park, Yong Beom Cho, Seung Tae Kim, Yong Soo Choi, Jeeyun Lee; Received July 3, 2025 Accepted December 8, 2025 Published online December 17, 2025; DOI: https://doi.org/10.4143/crt.2025.691 [Accepted]

Abstract PDF Supplementary Material: Purpose
Colorectal cancer (CRC) lung metastases exhibit high recurrence rates after resection, underscoring the need for improved therapeutic strategies. This study aimed to characterize the tumor microenvironment (TME) of CRC lung metastases and identify the factors associated with recurrence.
Materials and Methods
Fifteen CRC patients who underwent lung metastasectomy were enrolled. Multiplex immunohistochemistry (IHC), whole exome sequencing, transcriptome profiling, and single-cell RNA sequencing (scRNA-seq) were conducted on matched tumor, adjacent and distant normal lung tissues. Immune cell populations and gene expression profiles were analyzed and correlated with clinical recurrence outcomes.
Results
Exome and transcriptome analyses revealed frequent TP53, KRAS, and APC mutations. Most tumors corresponded to consensus molecular subtypes 2 and 4, characterized by immune-depleted and fibrotic features. Tumors showed downregulation of effector T and NK cell signatures. IHC revealed reduced density and increased distance of CD8+ T cells and macrophages from the epithelial cells. scRNA-seq demonstrated increased regulatory T cells and decreased NK and effector T cells in tumor. Tumor-associated macrophages (TAMs), particularly SPP1 (osteopontin)-expressing subsets, were markedly enriched in tumor and correlated with suppressed effector T cella activity. High SPP1 expression was associated with early recurrence and poor overall survival. Patients with recurrence had higher proportion of PD-1+ CD8+ T cells in adjacent normal tissues.
Conclusion
Immunosuppressive features including enrichment of SPP1+ TAMs and depletion of effector T and NK cells contribute to recurrence after CRC lung metastasectomy. Therapeutic strategies targeting both TAMs and T cells may enhance clinical outcomes in this patient population.

750 View
62 Download

Lung and Thoracic cancer

Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non–Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial: Junghoon Shin, Sehhoon Park, Kyung Hwan Kim, Eui-Cheol Shin, Hyun Ae Jung, Jong Ho Cho, Jong-Mu Sun, Se-Hoon Lee, Yong Soo Choi, Jin Seok Ahn, Jhingook Kim, Keunchil Park, Young Mog Shim, Hong Kwan Kim, Jae Myoung Noh, Yong Chan Ahn, Hongryull Pyo, Myung-Ju Ahn; Cancer Res Treat. 2024;56(4):1084-1095. Published online April 30, 2024; DOI: https://doi.org/10.4143/crt.2024.084

Abstract PDF Supplementary Material PubReader ePub

Purpose
Optimal treatment for stage IIIA/N2 non–small cell lung cancer (NSCLC) is controversial. We aimed to assess the efficacy and safety of adjuvant pembrolizumab for stage IIIA/N2 NSCLC completely resected after neoadjuvant concurrent chemoradiation therapy (CCRT).
Materials and Methods
In this open-label, single-center, single-arm phase 2 trial, patients with stage IIIA/N2 NSCLC received adjuvant pembrolizumab for up to 2 years after complete resection following neoadjuvant CCRT. The primary endpoint was disease-free survival (DFS). Secondary endpoints included overall survival (OS) and safety. As an exploratory biomarker analysis, we evaluated the proliferative response of blood CD39⁺PD-1⁺CD8⁺ T cells using fold changes in the percentage of proliferating Ki-67⁺ cells from days 1 to 7 of cycle 1 (Ki-67_D7/D1).
Results
Between October 2017 and October 2018, 37 patients were enrolled. Twelve (32%) and three (8%) patients harbored EGFR and ALK alterations, respectively. Of 34 patients with programmed cell death ligand 1 assessment, 21 (62%), nine (26%), and four (12%) had a tumor proportion score of < 1%, 1%-50%, and ≥ 50%, respectively. The median follow-up was 71 months. The median DFS was 22.4 months in the overall population, with a 5-year DFS rate of 29%. The OS rate was 86% at 2 years and 76% at 5 years. Patients with tumor recurrence within 6 months had a significantly lower Ki-67D7/D1 among CD39⁺PD-1⁺CD8⁺ T cells than those without (p=0.036). No new safety signals were identified.
Conclusion
Adjuvant pembrolizumab may offer durable disease control in a subset of stage IIIA/N2 NSCLC patients after neoadjuvant CCRT and surgery.

Citations

Citations to this article as recorded by

Adjuvant immunotherapy improves survival in completely resected stage IB–III NSCLC: a systematic review and meta-analysis
Hong Huang, Pengchen Bao, Hongyu Jin, Wenyang Li, Hui Shen, Zhen Qin, Ying Pan, Xinming Su, Delei Kong
Frontiers in Oncology.2025;[Epub] CrossRef
Advances in molecular pathology and therapy of non-small cell lung cancer
Qing Huang, Yuanxiang Li, Yingdan Huang, Jingyi Wu, Wendai Bao, Chang Xue, Xiaoyu Li, Shuang Dong, Zhiqiang Dong, Sheng Hu
Signal Transduction and Targeted Therapy.2025;[Epub] CrossRef
A retrospective analysis of neoadjuvant chemotherapy in pneumonectomy for locally advanced central non–small cell lung cancer
Yuchen Wang, Zhihang Dang, Pu Jiang, Zhifeng Li, Jin Yang, Kun Gao, Xiaona Chen, Jifang Yao
PeerJ.2025; 13: e20007. CrossRef

5,618 View
177 Download
3 Web of Science
3 Crossref

Gastrointestinal cancer

Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study: Sehhoon Park, Yurimi Lee, Jiyun Lee, Yang Won Min, Hong Kwan Kim, Joon Young Choi, Hyun Ae Jung, Yong Soo Choi, Yoon-La Choi, Young Mog Shim, Jong-Mu Sun; Cancer Res Treat. 2024;56(2):567-579. Published online October 16, 2023; DOI: https://doi.org/10.4143/crt.2023.897

Abstract PDF Supplementary Material PubReader ePub

Purpose
Programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors have shown efficacy in metastatic esophageal squamous cell carcinoma (ESCC) therapy. However, data is still limited regarding neoadjuvant immunotherapy for operable ESCC.
Materials and Methods
Patients with clinical stage T2 or T3 and N0 ESCC received three cycles of nivolumab therapy every two weeks before surgical resection. The primary endpoint is major pathologic responses (MPR) rate (≤ 10% of residual viable tumor [RVT]).
Results
Total 20 patients completed the planned nivolumab therapy. Among them, 17 patients underwent surgery as protocol, showing MPR in two patients (MPR rate, 11.8%), including one pathologic complete response, on conventional pathologic response evaluation. Pathologic response was re-evaluated using the immune-related pathologic response criteria based on immune-related RVT (irRVT). Three patients were classified as immunologic major pathologic response (iMPR; ≤ 10% irRVT, iMPR rate: 17.6%), five as pathologic partial response (> 10% and < 90% irRVT), and nine as pathologic nonresponse (≥ 90% irRVT). The combined positive score (CPS) for PD-L1 in the baseline samples was predictable for iMPR, with the probability as 37.5% in CPS ≥ 10 (3/8) and 0% in CPS < 10 (0/9).
Conclusion
Although the efficacy of neoadjuvant nivolumab therapy was modest in unselected ESCC patients, further researches on neoadjuvant immunotherapy are necessary in patients with PD-L1 expressed ESCC.

Citations

Citations to this article as recorded by

Low Serum Interleukin-6 Levels Enhance the Efficacy of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
Yawei Wang, Ye Hu, Yi Qin, Xiangfeng Jin, Yandong Zhao
Cancer Biotherapy and Radiopharmaceuticals.2025; 40(10): 768. CrossRef
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort
J.S. Deutsch, R.A. Scolyer, E. Burton, K.J. Busam, K.Y. Chen, A. Cimino-Mathews, T.R. Cottrell, C.E. de Andrea, P.O. Fiset, G.V. Long, J. Messina, R.V. Rawson, R. Salgado, C.M. Schürch, R.R. Seethala, L.M. Sholl, S. Signoretti, S.L. Topalian, B.A. van de
Annals of Oncology.2025;[Epub] CrossRef
Prognostic role of effective radiation dose to immune cells in esophageal cancer treated with definitive chemoradiation
Yoo Kyung Choi, Seok Hyun Son, Hong Seok Jang, In-Ho Kim, Sea-Won Lee, Soo-Yoon Sung, Satyajeet Rath
PLOS One.2025; 20(11): e0336794. CrossRef

6,098 View
185 Download
4 Web of Science
3 Crossref

Lung and Thoracic cancer

Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology–Based EGFR Mutation Assay in Patients with Operable Non–Small Cell Lung Cancer: Il-Hyun Park, Dae-Soon Son, Yoon-La Choi, Ji-Hyeon Choi, Ji-Eun Park, Yeong Jeong Jeon, Minseob Cho, Hong Kwan Kim, Yong Soo Choi, Young Mog Shim, Jung Hee Kang, Suzy Park, Jinseon Lee, Sung-Hyun Kim, Byung-Chul Lee, Jhingook Kim; Cancer Res Treat. 2024;56(1):81-91. Published online June 20, 2023; DOI: https://doi.org/10.4143/crt.2023.408

Abstract PDF Supplementary Material PubReader ePub

Purpose
Recently, we developed allele-discriminating priming system (ADPS) technology. This method increases the sensitivity of conventional quantitative polymerase chain reaction up to 100 folds, with limit of detection, 0.01%, with reinforced specificity. This prospective study aimed to develop and validate the accuracy of ADPS epidermal growth factor receptor (EGFR) Mutation Test Kit using clinical specimens.
Materials and Methods
In total 189 formalin-fixed paraffin-embedded tumor tissues resected from patients with non–small cell lung cancer were used to perform a comparative evaluation of the ADPS EGFR Mutation Test Kit versus the cobas EGFR Mutation Test v2, which is the current gold standard. When the two methods had inconsistent results, next-generation sequencing–based CancerSCAN was utilized as a referee.
Results
The overall agreement of the two methods was 97.4% (93.9%-99.1%); the positive percent agreement, 95.0% (88.7%-98.4%); and the negative percent agreement, 100.0% (95.9%-100.0%). EGFR mutations were detected at a frequency of 50.3% using the ADPS EGFR Mutation Test Kit and 52.9% using the cobas EGFR Mutation Test v2. There were 10 discrepant mutation calls between the two methods. CancerSCAN reproduced eight ADPS results. In two cases, mutant allele fraction was ultra-low at 0.02% and 0.06%, which are significantly below the limit of detection of the cobas assay and CancerSCAN. Based on the EGFR genotyping by ADPS, the treatment options could be switched in five patients.
Conclusion
The highly sensitive and specific ADPS EGFR Mutation Test Kit would be useful in detecting the patients who have lung cancer with EGFR mutation, and can benefit from the EGFR targeted therapy.

Citations

Citations to this article as recorded by

Highly Sensitive 3D‐Nanoplasmonic‐Based Epidermal Growth Factor Receptor Mutation Multiplex Assay Chip for Liquid Biopsy
Ji Young Lee, Byeong‐Ho Jeong, Ho Sang Jung, Taejoon Kang, Yeonkyung Park, Jin Kyung Rho, Sung‐Gyu Park, Min‐Young Lee
Small Science.2024;[Epub] CrossRef
The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer
Adam Szpechcinski, Joanna Moes-Sosnowska, Paulina Skronska, Urszula Lechowicz, Magdalena Pelc, Malgorzata Szolkowska, Piotr Rudzinski, Emil Wojda, Krystyna Maszkowska-Kopij, Renata Langfort, Tadeusz Orlowski, Pawel Sliwinski, Mateusz Polaczek, Joanna Chor
International Journal of Molecular Sciences.2024; 25(14): 7908. CrossRef

6,292 View
329 Download
2 Web of Science
2 Crossref

Gastrointestinal cancer

The Role of Adjuvant Chemotherapy after Neoadjuvant Chemoradiotherapy Followed by Surgery in Patients with Esophageal Squamous Cell Carcinoma: Seong Yong Park, Hong Kwan Kim, Yeong Jeong Jeon, Junghee Lee, Jong Ho Cho, Yong Soo Choi, Young Mog Shim, Jae Il Zo; Cancer Res Treat. 2023;55(4):1231-1239. Published online April 24, 2023; DOI: https://doi.org/10.4143/crt.2022.1417

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to investigate the efficacy of adjuvant chemotherapy after neoadjuvant chemoradiotherapy (CCRTx) followed by surgery in patients with esophageal squamous cell carcinoma (ESCC).
Materials and Methods
We retrospectively analyzed the data from 382 patients who received neoadjuvant CCRTx and esophagectomy for ESCC between 2003 and 2018.
Results
This study included 357 (93.4%) men, and the years median patient age was 63 (range, 40 to 84 years). Overall, 69 patients (18.1%) received adjuvant chemotherapy, whereas 313 patients (81.9%) did not. The median follow-up period was 28.07 months (interquartile range, 15.50 to 62.59). The 5-year overall survival (OS) and disease-free survival were 47.1% and 42.6%, respectively. Adjuvant chemotherapy did not improve OS in all patients, but subgroup analysis revealed that adjuvant chemotherapy improved the 5-year OS in patients with ypT+N+ (24.8% vs. 29.9%, p=0.048), whereas the survival benefit of adjuvant chemotherapy was not observed in patients with ypT0N0, ypT+N0, or ypT0N+. Multivariable analysis revealed that ypStage and adjuvant chemotherapy (hazard ratio, 0.601; p=0.046) were associated with OS in patients with ypT+N+. Freedom from distant metastasis was marginally different according to the adjuvant chemotherapy (48.3% vs. 41.3%, p=0.141).
Conclusion
Adjuvant chemotherapy after neoadjuvant therapy followed by surgery reduces the distant metastasis in ypT+N+ ESCC patients, thereby improving the OS. The consideration could be given to administration of adjuvant chemotherapy to ypT+N+ ESCC patients with tolerable conditions.

Citations

Citations to this article as recorded by

Postoperative Adjuvant Therapy Benefits Non‐pCR Patients Rather Than pCR Patients for Locally Advanced ESCC: A Multicenter Real‐World Study
Defeng Liu, Ao Liu, Longxiang Guo, Yi Li, Yuanlin Li, Yuxiang Chi, Haiqun Lin, Jinming Yu, Minghuan Li
Thoracic Cancer.2025;[Epub] CrossRef
Prognostic role of effective radiation dose to immune cells in esophageal cancer treated with definitive chemoradiation
Yoo Kyung Choi, Seok Hyun Son, Hong Seok Jang, In-Ho Kim, Sea-Won Lee, Soo-Yoon Sung, Satyajeet Rath
PLOS One.2025; 20(11): e0336794. CrossRef
Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study
Shu-Han Xie, Li-Tao Yang, Hai Zhang, Zi-Lu Tang, Zhi-Wei Lin, Yi Chen, Zhi-Nuan Hong, Rong-Yu Xu, Wan-Li Lin, Ming-Qiang Kang
Frontiers in Immunology.2024;[Epub] CrossRef
Clinical implications of C-reactive protein–albumin–lymphocyte (CALLY) index in patients with esophageal cancer
Ruiya Ma, Yoshinaga Okugawa, Tadanobu Shimura, Shinji Yamashita, Yuhki Sato, Chengzeng Yin, Ryo Uratani, Takahito Kitajima, Hiroki Imaoka, Mikio Kawamura, Yuhki Morimoto, Yoshiki Okita, Shigeyuki Yoshiyama, Masaki Ohi, Yuji Toiyama
Surgical Oncology.2024; 53: 102044. CrossRef
Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study
Jifeng Feng, Liang Wang, Xun Yang, Qixun Chen
Frontiers in Immunology.2024;[Epub] CrossRef

5,216 View
170 Download
8 Web of Science
5 Crossref

Lung and Thoracic cancer

The Role of Adjuvant Therapy Following Surgical Resection of Small Cell Lung Cancer: A Multi-Center Study: Seong Yong Park, Samina Park, Geun Dong Lee, Hong Kwan Kim, Sehoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Tae Hee Hong, Yong Soo Choi, Jhingook Kim, Jong Ho Cho, Young Mog Shim, Jae Ill Zo, Kwon Joong Na, In Kyu Park, Chang Hyun Kang, Young-Tae Kim, Byung Jo Park, Chang Young Lee, Jin Gu Lee, Dae Joon Kim, Hyo Chae Paik; Cancer Res Treat. 2023;55(1):94-102. Published online June 9, 2022; DOI: https://doi.org/10.4143/crt.2022.290

Abstract PDF Supplementary Material PubReader ePub

Purpose
This multi-center, retrospective study was conducted to evaluate the long-term survival in patients who underwent surgical resection for small cell lung cancer (SCLC) and to identify the benefit of adjuvant therapy following surgery.
Materials and Methods
The data of 213 patients who underwent surgical resection for SCLC at four institutions were retrospectively reviewed. Patients who received neoadjuvant therapy or an incomplete resection were excluded.
Results
The mean patient age was 65.29±8.93 years, and 184 patients (86.4%) were male. Lobectomies and pneumonectomies were performed in 173 patients (81.2%), and 198 (93%) underwent systematic mediastinal lymph node dissections. Overall, 170 patients (79.8%) underwent adjuvant chemotherapy, 42 (19.7%) underwent radiotherapy to the mediastinum, and 23 (10.8%) underwent prophylactic cranial irradiation. The median follow-up period was 31.08 months (interquartile range, 13.79 to 64.52 months). The 5-year overall survival (OS) and disease-free survival were 53.4% and 46.9%, respectively. The 5-year OS significantly improved after adjuvant chemotherapy in all patients (57.4% vs. 40.3%, p=0.007), and the survival benefit of adjuvant chemotherapy was significant in patients with negative node pathology (70.8% vs. 39.7%, p=0.004). Adjuvant radiotherapy did not affect the 5-year OS (54.6% vs. 48.5%, p=0.458). Age (hazard ratio [HR], 1.032; p=0.017), node metastasis (HR, 2.190; p < 0.001), and adjuvant chemotherapy (HR, 0.558; p=0.019) were associated with OS.
Conclusion
Adjuvant chemotherapy after surgical resection in patients with SCLC improved the OS, though adjuvant radiotherapy to the mediastinum did not improve the survival or decrease the locoregional recurrence rate.

Citations

Citations to this article as recorded by

Application of postoperative adjuvant radiotherapy in limited-stage small cell lung cancer: A systematic review and meta-analysis
Chuanhao Zhang, Genghao Zhao, Huajian Wu, Jianing Jiang, Wenyue Duan, Zhijun Fan, Zhe Wang, Ruoyu Wang
Radiotherapy and Oncology.2024; 193: 110123. CrossRef
A 15-Gene-Based Risk Signature for Predicting Overall Survival in SCLC Patients Who Have Undergone Surgical Resection
Sevcan Atay
Cancers.2023; 15(21): 5219. CrossRef

8,478 View
152 Download
4 Web of Science
2 Crossref

Lung Cancer

Conditional Survival of Surgically Treated Patients with Lung Cancer: A Comprehensive Analyses of Overall, Recurrence-free, and Relative Survival: Dong Wook Shin, Jong Ho Cho, Jung Eun Yoo, Juhee Cho, Dong Woog Yoon, Genehee Lee, Sumin Shin, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Jae Ill Zo, Young Mog Shim; Cancer Res Treat. 2021;53(4):1057-1071. Published online March 9, 2021; DOI: https://doi.org/10.4143/crt.2020.1308

Abstract PDF PubReader ePub

Purpose
Survival probability changes over time in cancer survivors. This study examined conditional survival in patients undergoing curative resection for non-small cell lung cancer (NSCLC).
Materials and Methods
Five-year conditional recurrence-free survival (CRFS), conditional overall survival (COS), and conditional relative survival (CRS) up to 10 years after surgery were calculated in patients who underwent NSCLC resection from 1994 to 2016. These rates were stratified according to age, sex, year of diagnosis, pathological stage, tumor histology, smoking status, comorbidity, and lung function.
Results
Five-year CRFS increased from 65.6% at baseline to 90.9% at 10 years after surgery. Early differences in 5-year CRFS according to stratified patient characteristics disappeared, except for age: older patients exhibited persistently lower 5-year CRFS. Five-year COS increased from 72.7% to 78.3% at 8 years and then decreased to 75.4% at 10 years. Five-year CRS increased from 79.0% at baseline to 86.8% at 10 years. Older age and higher pathologic stage were associated with lower 5-year COS and CRS up to 10 years after surgery. Female patients, those with adenocarcinoma histology, non-smokers, patient without comorbidities and had good lung function showed higher COS and CRS.
Conclusion
CRFS improved over time, but significant risk remained after 5 years. CRS slightly improved over time but did not reach 90%, suggesting significant excess mortality compared to the general population. Age and stage remained significant predictors of conditional survival several years after surgery. Our conditional survival estimates should help clinicians and patients make informed treatment and personal life decisions based on survivorship status.

Citations

Citations to this article as recorded by

Leveraging Landmark Analysis for Tailored Surveillance in Stage I Non-Small-Cell Lung Cancer
Giovanni Leuzzi, Federica Sabia, Matteo Calderoni, Clarissa Uslenghi, Ugo Pastorino, Alfonso Marchianò, Michele Ferrari, Alessandro Pardolesi, Daniele Lorenzini, Giuseppe Lo Russo, Claudia Proto, Arsela Prelaj, Piergiorgio Solli
Cancers.2026; 18(3): 367. CrossRef
Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the ‘EVIDENCE’ study
Giannis Mountzios, Sofia Lampaki, Helena Linardou, Vassilis Georgoulias, Dimitrios Mavroudis, Stavros Anevlavis, Andriani Charpidou, Maria Lykka, Dionysis Spyratos, Evangelos G Sarris, Alvertos Somarakis, Christina Papista, Alexandros Glentis, Aristeidis
Future Oncology.2025; 21(4): 447. CrossRef
A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States
Amy L. Cummings, Jesse Sussell, Katherine L. Rosettie, Fadoua El Moustaid, Sarika Ogale, Celina Ngiam, Nick Jovanoski, Melina Arnold, Jay M. Lee
American Journal of Clinical Oncology.2025;[Epub] CrossRef
COL3A1‐positive endothelial cells influence LUAD prognosis and regulate LUAD carcinogenesis by NCL–PI3K–AKT axis
Moyan Zhang, Yicheng Liang, Peng Song
The Journal of Gene Medicine.2024;[Epub] CrossRef
Adjustment to “new normal” after cancer among non–small cell lung cancer survivors: A qualitative study
Genehee Lee, Soo Yeon Kim, Alice Ahn, Sunga Kong, Heesu Nam, Danbee Kang, Hong Kwan Kim, Young Mog Shim, Ansuk Jeong, Dong Wook Shin, Juhee Cho
Palliative and Supportive Care.2024; 22(3): 487. CrossRef
Spatial features of specific CD103+CD8+ tissue-resident memory T cell subsets define the prognosis in patients with non-small cell lung cancer
Guanqun Yang, Siqi Cai, Mengyu Hu, Chaozhuo Li, Liying Yang, Wei Zhang, Jujie Sun, Fenghao Sun, Ligang Xing, Xiaorong Sun
Journal of Translational Medicine.2024;[Epub] CrossRef
Supporting Life Adjustment in Patients With Lung Cancer Through a Comprehensive Care Program: Protocol for a Controlled Before-and-After Trial
Wonyoung Jung, Alice Ahn, Genehee Lee, Sunga Kong, Danbee Kang, Dongok Lee, Tae Eun Kim, Young Mog Shim, Hong Kwan Kim, Jongho Cho, Juhee Cho, Dong Wook Shin
JMIR Research Protocols.2024; 13: e54707. CrossRef
Conditional Survival of Patients with Limited-Stage Small Cell Lung Cancer After Surgery: A National Real-World Cohort Study
Jun-Peng Lin, Xiao-Feng Chen, Peiyuan Wang, Hao He, Wei-Jie Chen, Feng-Nian Zhuang, Hang Zhou, Yu-Jie Chen, Wen-Wei Wei, Shuo-Yan Liu, Feng Wang
Annals of Surgical Oncology.2024; 31(7): 4250. CrossRef
Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System
Qiran Wei, Yifang Liang, Jiahui Mao, Xin Guan
Cancer Medicine.2024;[Epub] CrossRef
Bioinformatics-based modeling of lung squamous cell carcinoma prognosis and prediction of immunotherapy response
Qiqing Zhang, Haidong He, Yi Wei, Guoping Li, Lu Shou
Discover Oncology.2024;[Epub] CrossRef
Dynamic evaluation of postoperative survival in intrahepatic cholangiocarcinoma patients who did not undergo lymphadenectomy: a multicenter study
Tingfeng Huang, Jie Kong, Hongzhi Liu, Zhipeng Lin, Qizhu Lin, Jianying Lou, Shuguo Zheng, Xinyu Bi, Jianming Wang, Wei Guo, Fuyu Li, Jian Wang, Yamin Zheng, Jingdong Li, Shi Cheng, Weiping Zhou, Yongyi Zeng
Scandinavian Journal of Gastroenterology.2023; 58(2): 178. CrossRef
A2aR on lung adenocarcinoma cells: A novel target for cancer therapy via recruiting and regulating tumor-associated macrophages
Ying Bai, Xin Zhang, Jiawei Zhou, Jianqiang Guo, Yafeng Liu, Chao Liang, Wenyang Wang, Yingru Xing, Jing Wu, Dong Hu
Chemico-Biological Interactions.2023; 382: 110543. CrossRef
Survival and Quality-of-life Outcomes in Early-Stage NSCLC Patients: a Literature Review of Real-World Evidence
Nick Jovanoski, Kathleen Bowes, Audrey Brown, Rossella Belleli, Danilo Di Maio, Shkun Chadda, Seye Abogunrin
Lung Cancer Management.2023;[Epub] CrossRef
Conditional survival analysis of patients with resected non–small cell lung cancer
Talib Chaudhry, Vaishnavi Krishnan, Andrew E. Donaldson, Zachary M. Palmisano, Sanjib Basu, Nicole M. Geissen, Justin M. Karush, Gillian C. Alex, Jeffrey A. Borgia, Michael J. Liptay, Christopher W. Seder
JTCVS Open.2023; 16: 948. CrossRef
Clinical Value of Surveillance 18F-fluorodeoxyglucose PET/CT for Detecting Unsuspected Recurrence or Second Primary Cancer in Non-Small Cell Lung Cancer after Curative Therapy
Chae Hong Lim, Soo Bin Park, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Yong Chan Ahn, Myung-ju Ahn, Joon Young Choi
Cancers.2022; 14(3): 632. CrossRef
Primary care‐based lung and breast cancer control in China: A commentary on lessons learnt from Korea
Heng Piao, Harry H. X. Wang, Hyejin Lee, Mingyang Yu, Belong Cho
European Journal of Cancer Care.2022;[Epub] CrossRef
Conditional survival nomogram predicting real-time prognosis of locally advanced breast cancer: Analysis of population-based cohort with external validation
Xiangdi Meng, Furong Hao, Zhuojun Ju, Xiaolong Chang, Yinghua Guo
Frontiers in Public Health.2022;[Epub] CrossRef

9,187 View
185 Download
15 Web of Science
17 Crossref

Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience: Hyojung Park, Dongryul Oh, Yong Chan Ahn, Hongryull Pyo, Jae Myung Noh, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Jae Ill Zo, Young Mog Shim; Cancer Res Treat. 2017;49(4):880-889. Published online December 12, 2016; DOI: https://doi.org/10.4143/crt.2016.442

Abstract PDF PubReader ePub

Purpose
The optimal adjuvant therapy modality for treating pN2 non-small cell lung cancer patients has not yet been established. In this study, the authors investigated clinical outcomes following three different adjuvant therapy modalities.
Materials and Methods
From January 2006 to December 2012, 240 patients with cN0/1 disease were found to have pN2 disease following curative resection and received one of three adjuvant therapy modalities:thoracic radiation therapy (TRT) and concurrent chemotherapy (CTx) (CCRT) (group I), CCRT plus consolidation CTx (group II), and CTx alone (group III). TRT was delivered to 155 patients (groups I/II), and full dose CTxwas delivered to 172 patients either as a consolidative or a sole modality (group II/III).
Results
During 30 months of median follow-up, 44 patients died and 141 developed recurrence. The 5-year overall survival (OS), locoregional control (LRC), distant metastasis-free survival (DMFS), and disease-free survival (DFS) rates of all patients were 76.2%, 80.7%, 36.4%, and 29.6%, respectively. There was no difference in OS among groups. TRT (groups I/II) significantly improved LRC, full dose CTx (groups II/III) did DMFS, and CCRT plus consolidation CTx (group II) did DFS, respectively.
Conclusion
The current study could support that TRT could improve LRC and full dose CTx could improve DMFS and that CCRT plus consolidation CTx could improve DFS.

Citations

Citations to this article as recorded by

The effect of adjuvant chemoradiotherapy on survival after R0 resection for stage III-N2 nonsmall cell lung cancer: A meta-analysis
Dailong Li, Wanqiang Li, Yaqi Pang, Lu Xu, Xinhua Xu
Medicine.2022; 101(28): e29580. CrossRef
The efficacy of postoperative radiotherapy for patients with non-small cell lung cancer
Zexu Wang, Baixia Yang, Ping Zhan, Li Wang, Bing Wan
Journal of Cancer Research and Therapeutics.2022; 18(7): 1910. CrossRef

45,659 View
260 Download
3 Web of Science
2 Crossref

Case Report

A Case of Synchronous Double Primary Cancer of the Penis and Urinary Bladder: Yong Soo Cho, Jung-Ae Lee, Si Bum Kim, Soo Jung Gong, Joo Heon Kim, Seon Min Youn, Eun Tak Kim; Cancer Res Treat. 2010;42(1):53-56. Published online March 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.1.53

Abstract PDF PubReader ePub

Multiple primary cancers are the occurrence of more than two cancers of different origin in an individual. Penile cancer is a rare disease, and finding it combined with other cancers is even rarer. A 64-year-old man with a painful penile mass was referred to us from a primary urological clinic. We performed a biopsy of the penile mass and the histology revealed a well-differentiated squamous cell carcinoma. Abdominal computed tomography showed a localized bladder tumor with inguinal lymphadenopathy. The patient underwent a partial penectomy, transurethral resection of the bladder tumor and inguinal lymph node dissection. The histology of the bladder tumor was high-grade papillary carcinoma, and that of the lymph node was squamous cell carcinoma. The penile and bladder tumors were in stage II (T1N1M0) and stage I (T1N0M0), respectively. We successfully treated the patient with adjuvant radiotherapy and systemic chemotherapy.

Citations

Citations to this article as recorded by

A rare case report of synchronous renal cell carcinoma and penile carcinoma
Indra Prakash Mandal, Krishnendu Maiti, Debansu Sarkar
Annals of Medical Science & Research.2025; 4(2): 108. CrossRef
Synchronous Double Primary Cancer of the Penisand Urinary Bladder
Deora H
MOJ Surgery.2017;[Epub] CrossRef

10,186 View
93 Download
2 Crossref

First
Prev
Page of 1
Next
Last

Search